Discover
Adcetris (brentuximab vedotin) / Seattle Genetics, Takeda; Keytruda (pembrolizumab) / Merck (MSD)EHA25Virtual: A new paradigm in relapsed refractory Hodgkin lymphoma (PRNewswire) - Jun 12, 2020 - P3, N=304; KEYNOTE-204 (NCT02684292); Sponsor: Merck Sharp & Dohme Corp; "...the phase 3 KEYNOTE-204 study has compared the efficacy and safety of pembrolizumab with that of brentuximab vedotin in patients with R/R cHL....Pembrolizumab monotherapy showed statistically significant and clinically meaningful improvement in PFS compared with brentuximab vedotin (13.2 vs 8.3 months; hazard ratio [95% CI]: 0.65 [0.48-0.88]; P = 0.00271) with a safety profile that was consistent with the known profiles of each agent. In addition, the PFS benefit extended to key subgroups of patients with R/R cHL, including those with primary refractory disease or those who did not receive prior autologous SCT."azacitidine/rigosertib / Onconova, Knight Therap; Estybon (rigosertib) / Onconova, SymBio, Knight TherapOnconova Therapeutics announces presentation at the 25th Congress of the European Hematology Association (EHA) (GlobeNewswire) - Jun 12, 2020 - P3, N=360; INSPIRE (NCT02562443); Sponsor: Onconova Therapeutics, Inc; "Onconova Therapeutics, Inc…announced updated aggregated baseline genomic data from HMA-failure patients screened for the INSPIRE trial were presented in an e-poster at the virtual 25th Annual EHA Congress….As an exploratory endpoint, bone marrow samples were collected at baseline, months 2, 4 and 6, and every 6 months thereafter, as well as at the end of treatment, for mutational analysis…'RAS pathway mutations were observed more frequently in patients that progressed on HMA therapy than those that failed HMA therapy completely. Understanding the association between RAS mutations and prognoses in this MDS setting appears to be informative to the potential role of RAS-targeting agents such as rigosertib…'"Ninlaro (ixazomib) / TakedaTakeda presents positive data from clinical trial evaluating oral Ninlaro (ixazomib) in multiple myeloma as a first-line maintenance therapy (Businesswire) - Jun 12, 2020 - P3, N=706; TOURMALINE-MM4 (NCT02312258); Sponsor: Millennium Pharmaceuticals, Inc; "The TOURMALINE-MM4 trial achieved its primary endpoint, with treatment with NINLARO resulting in a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation (hazard ratio [HR] 0.659; CI: 95; p Calquence (acalabrutinib) / AstraZenecaCalquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials (AstraZeneca Press Release) - Jun 12, 2020 - P3, N=306; ASCEND (NCT02970318); Sponsor: Acerta Pharma BV; "In the final analysis of ASCEND, an estimated 82% of patients with relapsed or refractory CLL treated with Calquence remained alive and free from disease progression at 18 months compared with 48% of patients on rituximab combined with idelalisib or bendamustine.2 The trial previously met the primary endpoint of Independent Review Committee-assessed progression-free survival at the interim analysis."momelotinib (CYT 387) / Sierra Oncology; Jakafi oral (ruxolitinib) / Novartis, IncyteSierra Oncology reports favorable long-term safety and dose intensity data for momelotinib (Canada Newswire) - Jun 12, 2020 - P3, N=432; Simplify 1 (NCT01969838); Sponsor: Sierra Oncology, Inc; P3, N=156; (NCT02101268); Sponsor: Sierra Oncology, Inc; "'Consistent with prior data, and reflecting momelotinib's differentiated pharmacological profile, our new long-term safety analyses continue to show a rapid and sustained increase in hemoglobin levels during momelotinib therapy, in contrast to the significant decrease in hemoglobin for patients receiving ruxolitinib. Patients treated with momelotinib also experienced significantly higher mean platelet counts compared to those receiving ruxolitinib. Importantly, patients who switched from ruxolitinib to momelotinib also achieved a sustained improvement in both hemoglobin and platelets'"
